In a victory for the European Medicines Agency, a European court ruled the regulator can provide access to clinical trial data and other types of information over the objections of three drug makers that claimed greater transparency would come at the expense of their commercial secrets.

The cases have been closely watched as a test of transparency rules that the EMA implemented seven years ago, as well as a newer policy that permits the agency to release certain clinical trial data, while also agreeing to select redactions negotiated with companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that since this is a European matter, the ‘Merck’ in question might be more properly tagged “MS&D?” (Merck Sharp & Dhome)
    That takes nothing away from the valuable detail in the article, which one expects will be updated as usual by additional company comments, as they arrive.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy